Real-time classification can identify a previously unrecognized subset of high-risk patients with childhood B-cell acute lymphoblastic leukemia who have excellent chances for cure without further intensification of treatment.
Acute Lymphoblastic Leukemia
Children with acute lymphocytic leukemia and their parents commonly over-report the amount of daily oral chemotherapy the child takes to treat the most common blood cancer in children.
Genetic variants increase the risk of osteonecrosis in children under age 10 with acute lymphoblastic leukemia.
Researchers have identified a genetic variant, 2R thymidylate synthase polymorphism, that is associated with an increased risk for avascular necrosis in children with ALL.
PEG-asparaginase had both similar safety and efficacy to intramuscular native E coli l-asparaginase for the treatment of children with ALL in complete remission.
The combination of chemotherapy with the TKI ponatinib was an effective treatment for patients with newly diagnosed Ph-positive acute lymphoblastic leukemia.
Even in the absence of cranial radiation therapy, survivors of childhood acute lymphoblastic leukemia (ALL) have decreased neurocognitive function years later.
A single cycle of blinatumomab resulted in complete minimal residual disease response in 78% of patients with acute lymphoblastic leukemia.
The FDA has approved blinatumomab (Blincyto) for the treatment of patients with Philadelphia chromosome-negative precursor B-cell acute lymphoblastic leukemia.
Treatment of Adult Acute Lymphoblastic Leukemia (ALL) With a Focus on Emerging Investigational and Targeted Therapies
In this review, we will discuss the management of ALL in the adult population, in the context of the recently published guidelines from the NCCN. We will focus in particular on the strides being made in salvage and targeted approaches.